Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Ongoing Cash Burn APGE is well-capitalized with substantial liquidity and low debt, but remains highly speculative due to zero revenue, persistent losses, significant cash burn, and a demanding valuation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Tight range ⢠Limited momentum Support Level: $134.75â$134.85; stronger at $134.20â$134.30 Resistance Level: $134.97â$135.08 APGE is mildly bullish over the last month but range-bound, with a close above $135.08 needed for upside confirmation and a break below $134.20 signaling weakness.
Sentiment & News
Key News Insights: ⢠Acquisition Completed ⢠Immunology Expansion ⢠Guidance Reaffirmed AbbVie completed its acquisition of Apogee, adding late-stage immunology assets while reaffirming 2026 guidance.
AI Summary
APGE is no longer an investable standalone biotech after AbbVie's completed $135.11-per-share cash acquisition ended Nasdaq trading, so former shareholders should confirm receipt of consideration while any future upside and clinical risk from its pipeline now accrues solely to AbbVie.
Description
Apogee Therapeutics is a biotechnology firm developing biologic therapies for atopic dermatitis, COPD and related inflammatory and immunological conditions. Its lead programs are subcutaneously administered, extended half-life monoclonal antibodies advancing in AD and COPD, with additional earlier-stage antibody programs for AD. The company was founded in 2022 and is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | APGE | Apogee Therapeutics, Inc. | Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum. | Closed | +0.1% |
| Mar 26 | Apr 2 | APGE | Apogee Therapeutics, Inc. | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16âweek topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52âweek APEX Part A durability data released 2026â03â23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21âday ROC ~+10.8% and price ~9% above its 21âday SMA, the setup is a classic eventâdriven biotech hot idea. | Closed | +7.5% |